Last reviewed · How we verify
Deep vein thrombosis
Approved treatments
- Dabigatran etexilate (DE) · Pfizer Inc.
Dabigatran etexilate (DE) as oral capsule - Pradaxa · Boehringer Ingelheim
Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development. - Pradaxa · Generic (originally Boehringer Ingelheim)
Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Deep vein thrombosis patent landscape — cliff calendar, originator estates, attackable patents
- Deep vein thrombosis treatment landscape brief
- Deep vein thrombosis treatment updates RSS
Frequently asked questions about Deep vein thrombosis
What drugs treat Deep vein thrombosis?
Tracked treatments include Dabigatran etexilate (DE), Pradaxa.
What is the treatment for Deep vein thrombosis?
Standard treatment for Deep vein thrombosis includes Dabigatran etexilate (DE), Pradaxa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Deep vein thrombosis patent cliff · Deep vein thrombosis CI report
- Treatment: Dabigatran etexilate (DE) · Pfizer Inc.
- Treatment: Pradaxa · Boehringer Ingelheim
- Treatment: Pradaxa · Generic (originally Boehringer Ingelheim)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing